Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK.
Histopathology Department, The Royal Marsden Hospital, London, UK.
J Pathol. 2022 Apr;256(4):369-377. doi: 10.1002/path.5861. Epub 2022 Mar 3.
In situ follicular neoplasia (ISFN) is usually an occasional incidental finding in lymph nodes by BCL2 immunohistochemistry, and its true scale is unknown. We have identified six cases of follicular lymphoma (FL) with a history of solid neoplasm 4-16 years ago, from which ISFN was identified widely in the surgically cleared lymph nodes (LNs). Using clone-specific PCR and BaseScope in situ hybridisation with primers or probes specific to the VDJ or BCL2-IGHJ junction sequence, we confirmed the clonal identity among different ISFNs and overt-FL in each of the four cases successfully investigated. Mutation analyses of overt-FL by targeted next-generation sequencing identified multiple potential pathogenic changes involving CREBBP, EZH2, KMT2D, TNFRS14, and STAT6. Further investigations of these mutations in paired ISFNs using Fluidigm PCR and Illumina sequencing showed the presence of the FL-associated mutations in early lesions for two of the six cases investigated (CREBBP and KMT2D in one case and STAT6 in the other), with one case displaying stepwise accumulation of its observed mutations. Remarkably, there were considerable divergences in BCL2 variants among different ISFN-involved lymph nodes in all four cases successfully investigated, indicating ongoing intraclonal diversification by somatic hypermutation machinery. Our findings demonstrate widespread distribution of ISFN lesions, further implicating their dynamic nature with the neoplastic cells undergoing active trafficking and clonal evolution. © 2021 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
原位滤泡性肿瘤(ISFN)通常是通过 BCL2 免疫组化在淋巴结中偶然发现的,其真实范围尚不清楚。我们已经确定了 6 例滤泡性淋巴瘤(FL)病例,这些病例在 4-16 年前曾患有实体瘤,在手术清除的淋巴结(LNs)中广泛发现了 ISFN。使用克隆特异性 PCR 和 BaseScope 原位杂交,使用针对 VDJ 或 BCL2-IGHJ 连接序列的引物或探针,我们成功地在四个成功研究的病例中的每个病例中证实了不同的 ISFN 和显性-FL 之间的克隆同一性。通过靶向下一代测序对显性-FL 进行突变分析,确定了涉及 CREBBP、EZH2、KMT2D、TNFRS14 和 STAT6 的多个潜在致病性变化。进一步使用 Fluidigm PCR 和 Illumina 测序对配对的 ISFN 进行这些突变的研究表明,在研究的 6 例中的 2 例中(1 例为 CREBBP 和 KMT2D,另 1 例为 STAT6),早期病变中存在 FL 相关突变,其中 1 例显示出其观察到的突变的逐步积累。值得注意的是,在所有四个成功研究的病例中,不同的 ISFN 受累淋巴结之间的 BCL2 变体存在相当大的差异,这表明体细胞超突变机制使克隆内多样化持续进行。我们的研究结果表明 ISFN 病变广泛分布,进一步表明其动态性质与经历活跃迁移和克隆演变的肿瘤细胞有关。© 2021 作者。约翰威立父子公司代表英国和爱尔兰病理学学会出版的《病理学杂志》。